Peptide Or Protein Sequence Patents (Class 930/10)

  • Patent number: 8945940
    Abstract: The present invention provides variable mass labeling reagents, a set of the variable mass labeling reagents, and a multiplexed set of variable mass labeling reagents.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: February 3, 2015
    Assignee: Postech Academy-Industry Foundation
    Inventors: Seung Koo Shin, Jongcheol Seo, Min-Soo Suh, Hye-Joo Yoon
  • Patent number: 8637636
    Abstract: Methods, apparatus, systems, computer programs and computing devices related to biologically assembling and/or synthesizing peptides and/or proteins are disclosed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: January 28, 2014
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Edward K. Y. Jung, Lowell L. Wood, Jr.
  • Patent number: 8569229
    Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: October 29, 2013
    Assignee: The Children's Hospital of Philadelphia
    Inventor: Michael M. Grunstein
  • Patent number: 8541221
    Abstract: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: September 24, 2013
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Johns Hopkins University
    Inventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, Eitel Mpoudi Ngole
  • Patent number: 8330026
    Abstract: The invention relates to the use of NF-?B inducing kinase (NIK) and related molecules for the modulation of signal activities controlled by cytokines, and some new such molecules.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: December 11, 2012
    Assignee: Yeda Research and Development Co., Ltd., Weizmann Institute of Science
    Inventors: David Wallach, Parameswaran Ramakrishnan, Taisia Shmushkovich
  • Patent number: 8303962
    Abstract: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: November 6, 2012
    Assignee: C3 Jian, Inc.
    Inventors: Randal H. Eckert, Chris Kaplan, Jian He, Daniel K. Yarbrough, Maxwell Anderson, Jee-Hyun Sim
  • Patent number: 8188216
    Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a bivalent radical, a —(CH2)t- bivalent radical, or a covalent bond; and where part (T) is a -Y-L-Z- radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for their preparation of these compounds in a combinatorial manner, is also disclosed.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: May 29, 2012
    Assignee: Tranzyme Pharma Inc.
    Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
  • Patent number: 8008440
    Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z- radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: August 30, 2011
    Assignee: Tranzyme Pharma Inc.
    Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
  • Patent number: 7927605
    Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: April 19, 2011
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventor: Hilda Elizabeth Smith
  • Patent number: 7722880
    Abstract: The present invention is directed to the cloning, sequencing, expression, and characterization of an immunoreactive ferric binding protein (Fbp) (38-kDa) protein of Ehrlichia canis encoded by a polynucleotide therefor. In particular embodiments, the protein is employed in an immunogenic composition, such as a vaccine. Methods to induce an immune reaction in an individual with compositions of the invention are provided.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: May 25, 2010
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, David H. Walker, Christopher Kuyler Doyle
  • Patent number: 7544655
    Abstract: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen ?-chain C terminus denoted pre-C? possess cell attraction activities, and are useful in pharmaceutical compositions.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: June 9, 2009
    Assignee: Hadasit Medical Research Services & Development Company Ltd.
    Inventors: Gerard Marx, Raphael Gorodetsky
  • Patent number: 7544662
    Abstract: The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of treating obesity by administering to obese subjects an effective amount of the polypeptides of the present invention.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 9, 2009
    Assignee: Carle Development Foundation
    Inventors: Ralph A. Nelson, James D. Shoemaker
  • Patent number: 7531522
    Abstract: A method for the production of fungus resistant transgenic plants, plant cells or plant tissue comprising the introduction of an Ab, rAb, rAb fragment or fusion or vector of the invention or the vectors of the composition of the invention into the genome of a plant, plant cell or plant cell tissue and a transgenic plant cell comprising stably integrated into the genome a polynucleotide or vector of the invention or the vectors of the composition of the invention.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: May 12, 2009
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Dieter Peschen, Rainer Fischer, Stefan Schillberg, Yu-Cai Liao, Simone Dorfmüller
  • Patent number: 7491490
    Abstract: The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 17, 2009
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Teresa Compton, Adam Lloyd Feire
  • Patent number: 7485446
    Abstract: The present invention is a mutant retroviral protease which confers an increase in retroviral stability. Retroviruses expressing the instant mutant retroviral protease exhibit at least a 2-fold increase in infectivity half-life as compared to wild-type retrovirus. Unexpectedly, a Gly119Glu mutation in the protease enhances retroviral stability in the presence of various wild-type envelope proteins including wild-type amphotropic, ecotropic and 10A1 murine leukemia viruses. The improved stability of the mutant retrovirus leads to more facile virus production and enhanced infection efficiency.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: February 3, 2009
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Halong N. Vu, Daniel W. Pack, Joshua Ramsey
  • Patent number: 7378390
    Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 ?.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: May 27, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Børglum Kjeldsen, Svend Ludvigsen
  • Publication number: 20080115247
    Abstract: Enzymatic and chemical processes for the preparation of certain of 3-phenyl-2-arylalkylthiopropionic acid derivatives which have utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome are described and also certain novel intermediates used in these processes.
    Type: Application
    Filed: December 14, 2005
    Publication date: May 15, 2008
    Inventors: David Brown, John Peter Gilday, Philip Anthony Hopes, Jonathan David Moseley, Evan William Snape, Andrew Wells
  • Patent number: 7285618
    Abstract: Neutrophil attracting and activating factors that may already exist in normal cells are located. Polypeptides having neutrophil stimulating activity were isolated from an extract originating from a normal porcine heart, whereby the invention was completed. The invention provides (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO:1; (b) a polypeptide consisting of an amino acid sequence derived from the amino acid sequence of SEQ ID NO:3 by deletion, substitution, insertion or addition of one or more amino acids and having neutrophil stimulating activity; or (c) a polypeptide consisting of an amino acid sequence biologically equivalent to the amino acid sequence of said polypeptide (a) or (b).
    Type: Grant
    Filed: March 6, 2001
    Date of Patent: October 23, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Hidehito Mukai, Yoshisuke Nishi, Eisuke Munekata
  • Patent number: 7271242
    Abstract: Described is a nucleic acid coding for a protein called “cyplasin” that shows a preferential toxicity to autonomously growing mammalian cells. Cell death induced by this protein differs from both apoptosis and necrosis. An intracellular cell death which occurs when recombinantly preparing cyplasin in cell cultures can be avoided by removal of the secretion signal in the cyplasin sequence. This modification makes it possible to express the cyplasin in a mammalian cell culture which is preferable with regard to the glycosylation pattern of the obtained protein. Thus, the present invention also relates to a method of recombinantly producing a protein in eukaryotic cells, preferably mammalian cells, which is cytotoxic for said cells when applied externally.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: September 18, 2007
    Assignee: Cyplasin Biomedical, Ltd.
    Inventor: Christian Petzelt
  • Patent number: 7247703
    Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: July 24, 2007
    Assignee: University of Washington
    Inventors: Martin A Cheever, Mary L Disis
  • Patent number: 7169894
    Abstract: A process is disclosed by which a polynucleotide is directly synthesized from the peptide or protein that it encodes without the need for sequencing (or sequence analysis) of the peptide or protein. Information contained in the sequence of the peptide or protein is directly coupled, by the process of reverse translation, to the synthesis of the polynucleotide. The usefulness of reverse translation is that it facilitates the amplification of information held in the amino acid sequence (the primary structure) of an unknown protein or peptide. Amplification is useful for, among other things, the identification and/or scientific investigation of the peptide or protein.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: January 30, 2007
    Assignee: Mirari Biosciences, Inc.
    Inventor: Mark T. Martin
  • Patent number: 7144579
    Abstract: The present invention provides virus vectors of the family Paramyxoviridae in which the transcription start (S) sequence has been modified so as to modify the expression of genes located downstream thereof, a method for producing the vectors, and uses thereof. By measuring the transcription initiation efficiency of the S sequence of each gene carried by Sendai viruses (SeV), it was clarified that the S sequence of F gene has a significantly lower ability to promote transcription than the other three S sequences. When the S sequence of the F gene of wild type Sendai virus was substituted by the S sequence of the P/M/HN gene-type showing a high transcription initiation efficiency, the F gene of the resultant Sendai virus mutant and genes located downstream thereof show elevated expression levels. It was also revealed that this mutant proliferates more quickly than the wild type.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: December 5, 2006
    Assignee: DNAVEC Research, Inc.
    Inventors: Yoshiyuki Nagai, Atsushi Kato, Mamoru Hasegawa, Makoto Inoue
  • Patent number: 7128913
    Abstract: The present invention refers to conjugates of erythropoietin with poly(ethylene glycol) comprising an erythropoietin glycoprotein having an N-terminal ?-amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to one poly(ethylene glycol) group of the formula —CO—(CH2)x—(OCH2CH2)m—OR wherein the —CO of the poly(ethylene glycol) group forms an amide bond with said N-terminal ?-amino group; and wherein R is lower alkyl; x is 2 or 3; and m is from about 450 to about 1350.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: October 31, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Josef Burg, Alfred Engel, Reinhard Franze, Bernd Hilger, Hartmut Ernst Schurig, Wilhelm Tischer, Manfred Wozny
  • Patent number: 7129329
    Abstract: The present invention provides an isolated archael and bacterial heme binding protein which reversibly binds oxygen with a low affinity. The heme binding protein may be utilized as a blood substitute. The invention also provides a method for controlled storage of oxygen by contacting a bacterial heme binding protein with oxygen allowing the protein to bind and store oxygen. The also provides methods to sense gaseous ligands using the heme binding protein. In other embodiments, the invention provides chimeric proteins having a heme-binding domain of an isolated heme binding archael bacterial protein and a heterologous signaling domain.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: October 31, 2006
    Assignee: University of Hawaii
    Inventors: Maqsudul Alam, Randy Larsen
  • Patent number: 7118749
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: October 10, 2006
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
  • Patent number: 7115268
    Abstract: This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, and carrier-conjugates thereof. The invention also relates to serum antibodies induced by the peptides and carrier-conjugates and their use to prevent, treat, or protect against the toxic effects of most, if not all, of the staphylococcal and streptococcal toxins. The invention also relates to diagnostic assays and kits to detect the presence of staphylococcal and streptococcal toxins, or antibodies thereto. The invention also relates isolated and purified to nucleic acids encoding the peptides of the invention and transformed host cells containing those nucleic acids.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: October 3, 2006
    Assignee: The Rockefeller University
    Inventors: Jason D. Bannan, Kumar Visvanathan, John B. Zabriskie
  • Patent number: 7041635
    Abstract: The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: May 9, 2006
    Assignee: IN2GEN Co., Ltd.
    Inventors: Hun-Taek Kim, In-Young Song, Jae Won Choi, Jin-Wook Jang, Yong-Kook Kim, Ho Soon Lee, Yung-Jue Bang, Dae-Kee Kim
  • Patent number: 7012132
    Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: March 14, 2006
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 7005290
    Abstract: Novel human and mouse DNA sequences that encode the gene CG1CE, which, when mutated, is responsible for Best's macular dystrophy, are provided. Provided are genomic CG1CE DNA as well as cDNA that encodes the CG1CE protein. Also provided is CG1CE protein encoded by the novel DNA sequences. Methods of expressing CG1CE protein in recombinant systems are provided. Also provided are diagnostic methods that detect patients having mutant CG1CE genes.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: February 28, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Konstantin Petrukhin, C. Thomas Caskey, Michael Metzker, Claes Wadelius
  • Patent number: 7001729
    Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: February 21, 2006
    Assignee: Migenix Corp.
    Inventors: Christen M. Anderson, Robert E. Davis, William Clevenger, Sandra Eileen Wiley, Scott W. Miller, Tomas R. Szabo, Soumitra S. Ghosh, Walter H. Moos, Yazhong Pei
  • Patent number: 7001993
    Abstract: Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid sequence of natural human antithrombin is substituted by another amino acid. Preferable examples thereof are human antithrombin variants wherein the amino acid at position 78 is substituted by Phe; the amino acid at position 278 is substituted by Ala, Arg, Asn, Gly, His, Tyr or Val; the amino acid at position 378 is substituted by Lys, Asn or Val; and/or the amino acid at position 380 is substituted by Ala, Asp, Gly, His, lie, Leu, Asn, Pro, Arg, Thr, Tyr or Val.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: February 21, 2006
    Assignee: Aventis Pharma Ltd.
    Inventor: Takehiko Koide
  • Patent number: 6989367
    Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: January 24, 2006
    Assignee: Genset S.A.
    Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
  • Patent number: 6943233
    Abstract: Cyclic peptides which comprise, as a constituent chain or chains thereof, one or two amino acid sequences selected from the amino acid sequence Asn-Val-Ser-Glu-Ala-Asp-Asp-Arg-Tyr-Ile and the amino acid sequence Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr, and AIDS vaccines containing at least one of the cyclic peptides as an active ingredient. From the in vivo absorption and antibody expression viewpoint, a substituent group is preferably bound to at least one active group selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptides. The cyclic peptides can neutralize the second receptors which the HIV-1 virus utiliizes in the infection of humans therewith.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: September 13, 2005
    Assignee: Nissui Pharmaceutical Co., Ltd.
    Inventor: Shozo Shoji
  • Patent number: 6930086
    Abstract: This invention is directed to an erythropoietin mutein having in vivo biological activity for causing bone marrow cells to increase production of reticulocytes and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: August 16, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Wilhelm Tischer
  • Patent number: 6919080
    Abstract: A novel peptide obtained from Haemophilus paragallinarum has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: July 19, 2005
    Assignee: Juridical Foundation The Chemo-Sero Therapeutic Research Institute
    Inventors: Eiji Tokunaga, Masashi Sakaguchi, Kazuo Matsuo, Fukusaburo Hamada, Sachio Tokiyoshi
  • Patent number: 6906175
    Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 14, 2005
    Assignee: MIGENIX Corp.
    Inventors: Christen M. Anderson, Robert E. Davis, William Clevenger, Sandra Eileen Wiley, Scott W. Miller, Tomas R. Szabo, Soumitra S. Ghosh, Walter H. Moos, Yazhong Pei
  • Patent number: 6906174
    Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 14, 2005
    Assignee: Migenix Corp.
    Inventors: Christen M. Anderson, Robert E. Davis, William Clevenger, Sandra Eileen Wiley
  • Patent number: 6902908
    Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: June 7, 2005
    Assignee: Migenix Corp.
    Inventors: Christen M. Anderson, Robert E. Davis, William Clevenger, Sandra Eileen Wiley, Scott W. Miller, Tomas R. Szabo, Soumitra S. Ghosh, Walter H. Moos, Yazhong Pei
  • Patent number: 6887670
    Abstract: Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: May 3, 2005
    Assignee: MIGENIX Corp.
    Inventors: Christen M. Anderson, Robert E. Davis, Tomas R. Szabo, Soumitra S. Ghosh, Walter H. Moos, Yazhong Pei
  • Patent number: 6878813
    Abstract: The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: April 12, 2005
    Assignees: Temple University - of the Commonwealth System of Higher Education, University of Utah Research Foundation
    Inventors: Susan C. Bock, Veronique Picard, Pedram Zendehrouh
  • Patent number: 6846667
    Abstract: The present invention is based on the identification of a series of virulence genes in E. coli K1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: January 25, 2005
    Assignee: Microscience, Ltd.
    Inventors: Helen Rachel Crooke, Enda Elizabeth Clarke, Paul Howard Everest, Gordon Dougan, David William Holden, Jacqueline Elizabeth Shea, Robert Graham Feldman
  • Patent number: 6824659
    Abstract: A mutant staphylococcal alpha hemolysin polypeptide containing a heterologous analyte-binding amino acid which assembles into an analyte-responsive heptameric pore assembly in the presence of a wild type staphylococcal alpha hemolysin polypeptide, digital biosensors, and methods of detecting, identifying, and quantifying analytes are described.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: November 30, 2004
    Assignee: University of Massachusetts
    Inventors: Hagan Bayley, Orit Braha, John Kasianowicz, Eric Gouaux
  • Patent number: 6808706
    Abstract: A method for keeping the quality of an aqueous parenteral solution of thrombomodulin which is not in a frozen or freeze-dried state but in a liquid form in storage and distribution, characterized in that the aqueous thrombomodulin solution containing an effective amount of soluble thrombomodulin and a buffer component exhibiting a buffering activity in a pH range of 5 to 7.0 has a pH of 5 to 7.0 and that (a) the aqueous thrombomodulin solution further contains a surfactant and is in a state aseptically filled into a case or (b) the aqueous thrombomodulin solution is the form of a prefilled syringe preparation produced by aseptically filling the thrombomodulin solution into a syringe substantially without any empty space.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: October 26, 2004
    Assignee: Asaki Kasei Pharma Corporation
    Inventors: Masaki Yui, Akira Yokozawa, Tomoyo Murata, Kazuhisa Tsuruta, Hirotomo Shimizu
  • Patent number: 6809178
    Abstract: A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: October 26, 2004
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Bruce Blumberg
  • Patent number: 6790448
    Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: September 14, 2004
    Assignee: The Texas A&M University System University
    Inventors: Yi Xu, Magnus A. O. Hook
  • Patent number: 6770744
    Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 3, 2004
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 6767722
    Abstract: The present invention relates to muteins of human basic fibroblast growth factor with superagonist properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed is a method for stimulating cell division.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 27, 2004
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Barry A. Springer, Michael W. Pantoliano, Celia M. Sharp
  • Patent number: 6762280
    Abstract: In this application is described substrates for high-throughput assays of clostridial neurotoxin proteolytic activities. Two types of substrates are described for use in assays for the proteolytic activities of clostridial neurotoxins: (1) modified peptides or proteins that can serve as FRET substrates and (2) modified peptides or proteins that can serve as immobilized substrates. In both types a fluorescent molecules is present in the substrate, eliminating the requirement for the addition of a fluorigenic reagent. The assays described can be readily adapted for use in automated or robotic systems.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: July 13, 2004
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: James J. Schmidt, Robert G. Stafford
  • Patent number: 6759216
    Abstract: The development of inhibitory antibodies to blood coagulation factor VIII (fVIII) results in a severe bleeding tendency. These antibodies arise in patients with hemophilia A (hereditary fVIII deficiency) who have been transfused with fVIII. They also occur in non-hemophiliacs, which produces the condition acquired hemophilia. We describe a method to construct and express novel recombinant fVIII molecules which escape detection by existing inhibitory antibodies (low antigenicity fVIII) and which decrease the likelihood of developing inhibitory antibodies (low immunogenicity fVIII). In this method, fVIII is glycosylated at sites that are known to be antibody recognition sequences (epitopes). This produces the desired properties of low antigenicity fVIII and low (immunogenicity fVIII. The mechanism is similar to one used by viruses such as the AIDS virus, which glycosylates its surface proteins to escape detection by the immune system.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: July 6, 2004
    Assignee: Emory University
    Inventor: John S. Lollar
  • Patent number: 6743778
    Abstract: The present invention concerns therapeutic agents that mimic the activity of Apo-AI amphipathic helix peptide. In accordance with the present invention, the compounds of the invention comprise: a. a Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle, preferably an Fc domain, is covalently attached to the Apo-AI amphipathic helix peptide or Apo-AL amphipathic helix peptide-mimetic domain. The vehicle and the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain may be linked through the N- or C-terminus of the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, as described further below.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: June 1, 2004
    Assignee: Amgen Inc.
    Inventor: Tadahiko Kohno